Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BCAL Diagnostics Limited ( (AU:BDX) ) just unveiled an announcement.
BCAL Diagnostics Limited has announced the launch of Avantect® early detection blood tests for pancreatic and ovarian cancer in Australia, starting January 2026. This initiative, in partnership with ClearNote Health and facilitated by Sonic Healthcare’s pathology network, aims to provide nationwide access to these tests, which utilize advanced AI/ML algorithms for high predictive accuracy. The introduction of Avantect tests is expected to significantly enhance early cancer detection, offering more treatment options and potentially improving survival rates for patients.
The most recent analyst rating on (AU:BDX) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is an Australian healthcare company focused on early cancer detection. The company offers diagnostic tests such as BREASTESTplus™, a non-invasive blood test used alongside mammography to improve breast health diagnostics. BCAL holds an exclusive license with ClearNote Health Inc. for the distribution of Avantect cancer detection tests in Australia and New Zealand.
Average Trading Volume: 491,039
Technical Sentiment Signal: Buy
Current Market Cap: A$36.78M
Learn more about BDX stock on TipRanks’ Stock Analysis page.